Bhaskar Anand is CAO & VP at REATA PHARMACEUTICALS INC (RETA). They have made 6 open-market trades across 1 company since 2023, most recently 2026-10-08.
CIK 0001890784
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RETA | SELL | 2023-09-05 | 2023-09-07 | $169.20 | $137K | +1.4% | N/A | N/A |
| RETA | SELL | 2023-08-15 | 2023-08-17 | $168.73 | $68K | -0.1% | +1.8% | N/A |
| RETA | SELL | 2023-06-14 | 2023-06-16 | $102.11 | $478K | +9.6% | +20.0% | +86.9% |
| RETA | SELL | 2023-05-15 | 2023-05-17 | $85.37 | $93K | +10.2% | +14.7% | +107.8% |
| RETA | SELL | 2023-03-07 | 2023-03-08 | $84.58 | $14K | +9.4% | +15.0% | +15.0% |
| RETA | SELL | 2023-03-03 | 2023-03-06 | $87.47 | $143K | +2.8% | +6.0% | +5.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.